24/7 Market News Snapshot 26 November, 2024 – Poseida Therapeutics, Inc. Common Stock (NASDAQ:PSTX)

November 26, 2024

DENVER, Colo., 26 November, 2024 (247marketnews.com) – (NASDAQ:PSTX) are discussed in this article.
Poseida Therapeutics, Inc. is experiencing a notable surge, fueled by a definitive agreement from Roche to acquire the company for $9.00 per share, equating to an estimated equity value of around $1 billion. Currently trading at approximately $9.129, Poseida has shown an extraordinary increase of 219.20% from its previous close of $2.860, reflecting heightened investor confidence demonstrated by a trading volume of 722.88K shares.

The impending acquisition, expected to finalize in the first quarter of 2025, is part of Roche’s strategy to bolster its leadership in the allogeneic cell therapy sector. Poseida’s innovative focus on donor-derived CAR-T cell therapies positions it as a pioneer in the biopharmaceutical space. Noteworthy programs in its pipeline, such as P-BCMA-ALLO1—targeting B-cell maturation antigen for treating relapsed/refractory multiple myeloma—underscore its potential to revolutionize cell therapeutic approaches.

This acquisition, building on a collaboration initiated in 2022, aims to enhance Roche’s research and development capabilities, particularly in the areas of oncology, immunology, and neurology. Roche will gain access to Poseida’s advanced GMP manufacturing facilities and proprietary R&D assets, aiming to expedite the creation of allogeneic CAR-T therapies to meet diverse patient needs effectively.

Levi Garraway, Roche’s Chief Medical Officer, mentioned the strategic significance of the acquisition, emphasizing its capacity to facilitate advancements in cell therapy to enhance patient care. Following the transaction’s completion, Poseida’s talented workforce will integrate into Roche’s Pharmaceuticals Division, further driving innovation and reinforcing the company’s commitment to developing groundbreaking therapeutic solutions.

Related news for (PSTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.